A better understanding of the pathological mechanisms that drive neurodegeneration in
individuals with multiple sclerosis is needed to develop therapies that will effectively treat …

In patients with multiple sclerosis (MS), grey matter damage is widespread and might
underlie many of the clinical symptoms, especially cognitive impairment. This relation …

Importance There is a lack of validated biomarkers for disability progression independent of
relapse activity (PIRA) in multiple sclerosis (MS). Objective To determine how serum glial …

Importance Cognitive impairment is a common and disabling feature of multiple sclerosis
(MS), but a precise characterization of cognitive phenotypes in patients with MS is lacking …

Objective The aim of this work was to determine whether atrophy of specific retinal layers
and brain substructures are associated over time, in order to further validate the utility of …

Neuropsychiatric abnormalities may be broadly divided in two categories: disorders of
mood, affect, and behavior and abnormalities affecting cognition. Among these conditions …

Cognitive impairment is increasingly recognized to be a core feature of multiple sclerosis
(MS), with important implications for the everyday life of individuals with MS and for disease …

Pathological evaluation is the gold standard for identifying processes related to multiple
sclerosis that explain disease manifestations, and for guiding the development of new …

Multiple sclerosis (MS) and neuromyelitis optica (NMO) are autoimmune demyelinating
diseases of the central nervous system (CNS), having distinct immunological and …

Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric
manifestations have a high prevalence in MS patients and may worsen the illness …